Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2007

View Archived Issues

Summary of studies evaluating the effect of various natural products on diabetes

Profile of the antithrombotic agent rivaroxaban

Preclinical studies characterize the antithrombotic effect of MCC-977

Rapid, high-level platelet inhibition seen with PRT-060128 in humans

Antithrombotic activity seen with TGX-221 in vivo

Withaferin A holds promise as a potential drug lead

Alkaline phosphatase shows promise in ulcerative colitis

Peregrine acquires rights to antiangiogenesis technology from M.D. Anderson

ADL-5859 begins phase II pain study

Enrollment completed in phase II cardiovascular restenosis trial of Resten-MP

GRN-163L begins phase I/II study in advanced NSCLC

Biologics Menoflavon launched in Canada

Recent patents disclose novel antiinfective agents

DSM and Crucell sign licensing agreement with Masterclone to develop antibody

NPS and Nycomed expand Preotact agreement

Update on Karo Bio and Merck collaboration

CV Therapeutics identifies potential first-in-class MOA for ranolazine

Gilead initiates expanded access program for aztreonam lysine for CF

CB-7630 shows activity in prostate cancer trials

Nimotuzumab shown to bind to EGF receptor and potentiate radiotherapy

U.S. orphan drug designation for Corlux in Cushing's syndrome

New agents for gastrointestinal disorders described in recent patents

Zybrestat begins pivotal study in anaplastic thyroid cancer

Novel analgesic agents imparted in recent patent literature

NV-1020 shows promise in metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...